Vaccines: for human medicine

In 2024, vaccines: for human medicine trade exhibited significant decline, with global flows reaching $49,237,235,905 and a three-year compound annual growth rate of -24.8% (five-year: +9.0%). The all-time peak of $115,999,741,261 was recorded in 2021; the current level is 58% below that high-water mark.

Over the 30-year observation window (1995–2024), 79% of years recorded positive growth, indicating a predominantly expanding market. Trend momentum is decelerating (-31.4% acceleration).

The World Trade Flows Characterization classifies vaccines: for human medicine as "One-way trade" in the high price range price segment, providing additional context for market positioning and competitive dynamics.

The supply side is moderately concentrated (Herfindahl-Hirschman Index 0.179). The three largest exporters — Belgium ($14.6B), Ireland ($12.1B), and United States ($6.2B) — collectively dominate supply flows. The leading exporter has grown at -24.9% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.089). The three largest import markets are United States ($11.3B), Belgium ($6.9B), and Germany ($3.2B). The largest importing market sources from 39 different supplying countries.

Estimated substitution elasticity: -31.68. Buyers are highly price-sensitive and can switch between suppliers relatively easily.

The dominant trade corridor is Belgium → United States at $4.6B, representing 40.3% of the importer's total demand.

The volatility score for vaccines: for human medicine is 25 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, contracting demand signals caution before committing resources. A moderately concentrated market rewards differentiated positioning and strategic partner selection.

Data confidence is rated "High" based on reporting coverage and consistency across OECD member and partner countries.